Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A pilot study to compare the efficacy of a combination of apitherapy supplements versus placebo in children with autistic spectrum disorder.
A prospective, double-blind, placebo-controlled, crossover, multicentre clinical study which will enrol up to 45 children diagnosed with ASD (enrolment will stop when 40 children have completed the study). Children ages 3-14 will be tested before and after administering the combination of active substances (3 months) and placebo (3 months). The duration of participation in the study for each child will be 6 months. The supplements tested consist of three products - a combination of apitherapy and plant extracts - which have been approved for sale as individual supplements for more than 5 years in Romania - Apicol 12 gamma, Laptisor de matca activat (Royal Jelly) and Telom R Cerebral. Participation in the study is free and all children will be comparatively evaluated with the ATEC and ASRS scales and three sets of blood tests.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active combination | Active Comparator | A combination of 3 supplements with royal jelly and various plant extracts |
|
| Placebo combination | Placebo Comparator | A combination of 3 products with identical look and colour |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| A combination of apitherapy and plant extracts | Dietary Supplement | This combination contains the active comparator |
|
| Measure | Description | Time Frame |
|---|---|---|
| Modification on ATEC score | Total ATEC (Autism Treatment Evaluation Checklist) scores before and after each intervention, as well subscale scores; higher scores indicate worse status, score range between 0 (minimal, absence of pathology), to 180 - maximal intensity of symptoms | 3 months each of administration of active treatment and respectively placebo |
| Modification of ASRS scores | Scores on Autism Spectrum Rating Scales (ASRS) tests, total and 8 subscales will be compared before and after each intervention; total scores vary between 50-255, with higher score indicating more severe symptoms | 3 months each of administration of active treatment and respectively placebo |
| Measure | Description | Time Frame |
|---|---|---|
| NSE level modifications | Changes in the levels of serum Neuron-specific enolase (NSE) will be compared between the two arms, higher levels indicate higher neuronal destruction | 3 months each of administration of active treatment and respectively placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse effects | Adverse effects will be noted and compared for the two study arms | 3 months each of administration of active treatment and respectively placebo |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Felician Stancioiu, M.D. | Fundatia Bio-Forum | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinica Aide Sante | Bucharest | 040245 | Romania | |||
| Medical Link SRL |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37629593 | Background | Stancioiu F, Bogdan R, Dumitrescu R. Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD). Life (Basel). 2023 Aug 13;13(8):1736. doi: 10.3390/life13081736. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP_ICF | Yes | Yes | Yes | Study Protocol, Statistical Analysis Plan, and Informed Consent Form | Aug 9, 2024 | Dec 23, 2024 | Prot_SAP_ICF_000.pdf |
Not provided
| ID | Term |
|---|---|
| D000067877 | Autism Spectrum Disorder |
| ID | Term |
|---|---|
| D002659 | Child Development Disorders, Pervasive |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D010936 | Plant Extracts |
| ID | Term |
|---|---|
| D028321 | Plant Preparations |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided
prospective, double-blind, placebo-controlled, crossover, multicenter
Not provided
Not provided
Not provided
| Placebo Combination | Combination Product | A combination containing inert substances - placebo |
|
| Constanța |
| 900654 |
| Romania |